Revance Therapeutics set to go private with Crown Laboratories
Johnson City-based Crown Laboratories is now offering the public biotechnology company’s stockholders $3.65 per share of its ...
Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want ...
Hold Rating Maintained Amidst Revance Therapeutics Acquisition Uncertainty
Mizuho Securities analyst Uy Ear has maintained their neutral stance on RVNC stock, giving a Hold rating on January 17.Invest with Confidence: ...
Longview News-Journal19d
Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.
The "Crown" logo, PanOxyl and Blue Lizard are registered ... crown-laboratories-extension-of-tender-offer-to-acquire-revance-therapeutics-inc-302348826.html ...
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $8.39 Consensus Target Price from Brokerages
Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been assigned a consensus recommendation of “Hold” ...
Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com
Stock analysts at StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Get Free Report) in a ...
Revance Therapeutics Accepts Crown Increased Takeover Bid
Revance on Tuesday said it signed a revised merger agreement with privately held Crown, which has extended its tender offer for the Nashville, Tenn., biotechnology company to Feb. 4. Crown raised its ...